Sally Lord
Overview
Explore the profile of Sally Lord including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1014
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Horvath A, Bell K, Ceriotti F, Jones G, Loh T, Lord S, et al.
Clin Chem Lab Med
. 2024 Jun;
62(8):1474-1482.
PMID: 38836433
Analytical performance specifications (APS) based on outcomes refer to how 'good' the analytical performance of a test needs to be to do more good than harm to the patient. Analytical...
2.
Jones G, Bell K, Ceriotti F, Loh T, Lord S, Sandberg S, et al.
Clin Chem Lab Med
. 2024 May;
62(8):1531-1537.
PMID: 38801089
Analytical performance specifications (APS) are used for decisions about the required analytical quality of pathology tests to meet clinical needs. The Milan models, based on clinical outcome, biological variation, or...
3.
White S, Gong H, Zhu L, Doust J, Loh T, Lord S, et al.
J Clin Epidemiol
. 2021 Dec;
145:20-28.
PMID: 34965479
Objective: To determine the impact of test measurement variation on misclassification of prediabetes and diabetes in the US adult population. Study Design And Setting: Data from adults with no prior...
4.
Kok P, Lee K, Lord S, John T, Marschner I, Wu Y, et al.
Lung Cancer
. 2021 Dec;
163:14-18.
PMID: 34894454
Purpose: Response Evaluation Criteria in Solid Tumors (RECIST) has limitations but remains the conventional approach for tumor assessments. We explored whether circulating tumor DNA (ctDNA) can be incorporated into RECIST...
5.
Thompson M, Zigman Suchsland M, Hardy V, Lavallee D, Lord S, Devine E, et al.
BMJ Qual Saf
. 2021 Oct;
32(9):536-545.
PMID: 34615733
Background: Imaging tests are one of the most frequently used diagnostic modalities in healthcare, but the benefits of their direct impacts on clinical decision-making have been countered by concerns that...
6.
Kok P, Yoon W, Lord S, Marschner I, Friedlander M, Lee C
JCO Precis Oncol
. 2021 Jul;
5.
PMID: 34296055
Purpose: Many immune checkpoint inhibitors (ICIs) have been approved on the basis of tumor response end points in nonrandomized trials, including objective response rate (ORR) and duration and depth of...
7.
Chiam K, Carle C, Hughes S, Kench J, Woo H, Lord S, et al.
Prostate Cancer Prostatic Dis
. 2021 Mar;
24(3):662-673.
PMID: 33654249
Background: There is uncertainty on how multiparametric MRI (mpMRI) and MRI-targeted biopsy (MRI-TB) can be best used to manage low-risk prostate cancer patients on Active Surveillance (AS). We performed a...
8.
Kok P, Lee K, Lord S, Yang J, Rosell R, Goto K, et al.
Lung Cancer
. 2021 Mar;
154:113-117.
PMID: 33647577
Objectives: To assess the clinical utility of quantitative PCR (qPCR) assays, a routinely used test for detection of epidermal growth factor receptor (EGFR) mutation in circulating tumour DNA (ctDNA) in...
9.
Kok P, Cho D, Yoon W, Ritchie G, Marschner I, Lord S, et al.
JAMA Netw Open
. 2020 Sep;
3(9):e2011809.
PMID: 32897371
Importance: Progression-free survival (PFS) rate at 6 months has been proposed as a potential surrogate for overall survival (OS) rate at 12 months for immune checkpoint inhibitor (ICI) trials but...
10.
Naidoo P, Levett K, Lord S, Meagher A, Williams N, Aczel T
Aust Health Rev
. 2020 Aug;
45(1):36-41.
PMID: 32854817
Objectives This study estimated the frequency of ultrasounds ordered for clinically obvious inguinal hernias in patients referred to surgeons and evaluated the clinical value of ultrasonography for this patient population....